• editor@pphm.life
  • Evidence. Experts. Context.
Health news, backed by evidence.
PP Health Malaysia Banner PPHM

Cardiovascular Risk Assessment in Midlife Women: Have Screening Paradigms Kept Pace With Menopausal Transition Science?

Key Insights ▼

Cardiovascular disease (CVD) remains the leading cause of death among Malaysian women, yet midlife women are frequently categorised as low risk by conventional cardiovascular risk assessment tools.

This discordance arises from reliance on short term 10 year risk calculators, which are strongly weighted by age and often fail to capture the accelerated vascular changes occurring during the menopausal transition.

The result is a missed opportunity, a biologically vulnerable window when prevention could be most effective.

National Health and Morbidity Survey data highlight the magnitude of this issue. Among Malaysian women aged 45–59, over 40% have hypertension, 35% have dyslipidaemia and diabetes prevalence exceeds 15%.

Despite these figures, menopause status, vasomotor symptom burden and prior adverse pregnancy outcomes are rarely incorporated into routine cardiovascular risk assessment.

Consequently, women leave clinics reassured by a low 10-year risk scores if it is done at all, while their lifetime vascular risk steadily rises

Menopause as a Cardiovascular Stress Test

Large longitudinal cohorts particularly the Study of Women’s Health Across the Nation (SWAN) have consistently shown that adverse lipid shifts, increases in visceral adiposity, insulin resistance, and vascular dysfunction cluster around late perimenopause and early post-menopause and not simply with chronological ageing.

Furthermore, local studies suggest that a large proportion of midlife Malaysian women enter menopause with central obesity, suboptimal metabolic health, and low physical activity.

Moderate to severe vasomotor symptoms are still dismissed as quality of life issues despite mounting evidence linking them to endothelial dysfunction and carotid atherosclerosis.

Surgical menopause before the age of 50 has shown to increase risk of CVD as it abruptly terminates the cardioprotective effects of estrogen, leading to accelerated atherosclerosis.

Adverse obstetric history including preeclampsia and gestational diabetes serves as an early warning of vascular vulnerability.

Guidelines acknowledges all these factors as risk enhancers but without structured integration, these factors remain as theoretical acknowledgements rather than practical triggers for action.

Recognizing these factors allows clinicians to detect high-risk women before clinical disease manifests, offering a critical window for intervention.

Why Standard Risk Tools Underperform in Midlife Women?

Current risk assessment in Malaysia typically relies on the ASCVD 10-year risk calculator, Framingham Risk Score or informal risk judgement based on blood pressure, lipids, diabetes and smoking status.

While these tools are evidence based for older adults, they underrepresent younger midlife women because age dominates the score. A 50-year-old woman with moderate hypertension and dyslipidemia may still appear low risk over the next decade, even if she has had an early menopause and severe vasomotor symptoms.

Women may present late with their first cardiovascular event frequently after years of postmenopausal metabolic changes leaving clinicians with little opportunity for early prevention.

Cultural reluctance to discuss vasomotor, sleep, and mood symptoms combined with brief consultations and fragmented preventive care means menopause is often managed symptomatically, if at all, while cardiovascular risk assessment is deferred.

This gap is compounded in Malaysian practice, where care is often divided between primary care, cardiology and gynecology services. If menopause continues to be viewed solely as a reproductive milestone, women will continue to present late, often with established cardiovascular disease.

Embedding menopause focused cardiovascular screening into midlife care is therefore not an aspirational but an urgent, evidence-based necessity for Malaysia’s health system.

Bridging Cardiology and Menopause Care in Malaysia

Shifting from 10 year to lifetime cardiovascular risk is the cornerstone of menopause-focused assessment. Lifetime risk models, such as those promoted by the American Heart Association, provide a broader perspective, highlighting trajectories rather than short-term event probability.

Clinicians can integrate menopause-specific risk enhancers into these models, including age at menopause, vasomotor symptom severity, surgical menopause, and adverse pregnancy history.

Coronary artery calcium (CAC) scoring can further refine risk classification in midlife women. For those with borderline or intermediate 10-year risk, or multiple female-specific risk enhancers, CAC identifies subclinical atherosclerosis and supports earlier lifestyle or pharmacologic interventions.

While CAC remains underutilised in Malaysia, selective use could bridge the gap between guideline recommendations and clinical reality.

Reliance on LDL-cholesterol alone is particularly problematic in menopausal women. During estrogen withdrawal, lipid discordance is common where LDL-C may appear acceptable, while apo-Breflecting the total number of atherogenic particles, rises disproportionately.

Apo-B is especially informative in women with central adiposity, insulin resistance, elevated triglycerides and normal LDL-C during menopausal transition.

In these women, a normal LDL-C with an elevated Apo-B does not indicate low risk. It signals under recognized lifetime atherogenic burden. Contemporary guidelines already recognise elevated Apo-B as a risk enhancer, yet it remains underutilised in routine care.

High-sensitivity C-reactive protein (hs-CRP) is a validated marker of vascular inflammation and an independent predictor of cardiovascular events particularly in women. Large prospective cohorts, including the Women’s Health Study, demonstrate that hs-CRP predicts cardiovascular risk even when LDL-cholesterol is not elevated.

The JUPITER trial provided interventional evidence that individuals with raised hs-CRP benefit from statin therapy despite normal lipid levels. During the menopausal transition, hs-CRP rises in parallel with endothelial dysfunction and subclinical atherosclerosis, reflecting accelerated vascular aging not captured by traditional risk calculators.

Recognised by major guidelines as a risk enhancer, hs-CRP is therefore best used to refine lifetime cardiovascular risk in midlife women when short-term risk appears deceptively low in woman with enhanced risk factors.

Incorporating apoB and hs-CRP allows clinicians to identify women with high cumulative exposure long before clinical disease emerges. When uncertainty persists, coronary artery calcium scoring can further refine risk and support shared decision-making

Importantly, this approach shifts the focus from static thresholds to trajectories of vascular change. Rapid increases in LDL cholesterol, central adiposity, insulin resistance, or blood pressure after menopause signal escalating lifetime risk even when absolute values remain normal.

By reframing the conversation with patients, clinicians can emphasise that prevention is most effective when started early. Patient counselling should change to “Your short term risk is low, but your lifetime risk is rising and this is our prevention window.”

What Needs to Change in Malaysia

To integrate cardiovascular care into midlife woman in Malaysian practice, several steps are essential. We need to:

  1. Screen earlier during perimenopause, not years after menopause.
  2. Adopt lifetime risk perspectives, not just 10-year calculators
  3. Recognition of severity of vasomotor symptoms and reproductive history as cardiovascular risk enhancers.
  4. Use tools like Apo-B, hs-CRP and coronary artery calcium scoring more strategically in borderline-risk midlife women
  5. Integrate cardiovascular assessment into menopause care, rather than fragmenting it across specialties
  6. Cross-disciplinary collaboration between primary care, cardiology, and gynecology to ensure integrated preventive care.

Menopause clinics represent an underutilised opportunity for cardiovascular prevention. These settings already capture symptom burden, metabolic change and the critical timing window during which intervention has the greatest impact.

This is not about medicalising menopause. It is about recognizing it as a biological stress test, one that reveals who is likely to develop cardiovascular disease long before the first event occurs

Conclusion

The science is clear. The tools have evolved. The only thing lagging behind is our willingness to change. Menopause is not a benign transition we should simply get through. It is a window of opportunity, one we are currently missing.

If cardiovascular screening paradigms fail to incorporate menopausal transition science, then they are inequitable. The question is no longer whether menopause matters in cardiovascular risk. It is whether our systems are prepared to act on what we already know.

Menopause is a window of opportunity to prevent cardiovascular disease that so commonly shapes the second half of women’s lives.

References

Cook, N.R., Buring, J.E. and Ridker, P.M. (2012) ‘The effect of including C-reactive protein in cardiovascular risk prediction models for women’, Circulation, 125(5), pp. 598–606.

El Khoudary, S.R., Aggarwal, B., Beckie, T.M., et al. (2018) ‘Menopause transition and cardiovascular disease risk: implications for timing of early prevention’, Journal of the American College of Cardiology, 72(17), pp. 1928–1940.

Emerging Risk Factors Collaboration (2010) ‘C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis’, The Lancet, 375(9709), pp. 132–140.

Hodis, H.N. and Mack, W.J. (2021) ‘Menopausal hormone therapy and reduction of all-cause mortality and cardiovascular disease: the timing hypothesis’, Climacteric, 24(5), pp. 428–435.

Miedema, M.D., Duprez, D.A., Blaha, M.J., et al. (2021) ‘Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the Multi-Ethnic Study of Atherosclerosis’, JACC: Cardiovascular Imaging, 14(5), pp. 970–979.

Ridker, P.M., Buring, J.E., Cook, N.R. and Rifai, N. (2003) ‘C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events’, Circulation, 107(3), pp. 391–397.

Emerging Risk Factors Collaboration (2010) ‘C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis’, The Lancet, 375(9709), pp. 132–140.

Ridker, P.M., Danielson, E., Fonseca, F.A.H., et al. (2008) ‘Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein’, New England Journal of Medicine, 359(21), pp. 2195–2207.

Thurston, R.C., El Khoudary, S.R., Sutton-Tyrrell, K., et al. (2017) ‘Vasomotor symptoms and subclinical cardiovascular disease in the Study of Women’s Health Across the Nation’, Circulation, 135(8), pp. 761–773.

Visser, M., Bouter, L.M., McQuillan, G.M., Wener, M.H. and Harris, T.B. (1999) ‘Elevated C-reactive protein levels in overweight and obese adults’, JAMA, 282(22), pp. 2131–2135

Thurston, R.C., El Khoudary, S.R., Sutton-Tyrrell, K., et al. (2017) ‘Vasomotor symptoms and subclinical cardiovascular disease in the Study of Women’s Health Across the Nation’, Circulation, 135(8), pp. 761–773.

Institute for Public Health (IPH), Ministry of Health Malaysia (2020) National Health and Morbidity Survey (NHMS) 2019: Non-Communicable Diseases, Healthcare Demand and Health Literacy. Putrajaya: Ministry of Health Malaysia.

Nasir, K., Shaw, L.J., Budoff, M.J., et al. (2015) ‘Coronary artery calcium scanning should be used in asymptomatic patients at intermediate risk’, Journal of the American College of Cardiology, 66(15), pp. 1657–1669.

Blaha, M.J., Cainzos-Achirica, M., Greenland, P., et al. (2021) ‘Role of coronary artery calcium score in the evaluation and management of patients at risk for cardiovascular disease: a state-of-the-art review’, Journal of the American College of Cardiology, 78(19), pp. 1920–1932

Rocca, W.A., Grossardt, B.R., de Andrade, M., Malkasian, G.D. and Melton, L.J. (2006) ‘Survival patterns after oophorectomy in premenopausal women: a population-based cohort study’, The Lancet Oncology, 7(10), pp. 821–828.

Parker, W.H., Broder, M.S., Chang, E., et al. (2009) ‘Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study’, Obstetrics & Gynecology, 113(5), pp. 1027–1037

This article is authored by Dr. Cynthia R Govinda Kumar, an obstetric & gynaecology specialist. She is also the Menopause & Midlife Women’s Health Committee of the Obstetrical and Gynaecological Society of Malaysia.

Disclaimer: Editorial content on this site is for general information only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider with any questions about your health. While we take care to ensure accuracy, we make no guarantees and accept no responsibility for any errors, omissions, outdated information or any consequences arising from use of this site. Views expressed in articles, interviews and features are those of the authors or contributors and do not  necessarily reflect the views of the publisher. References to, or advertisements for, products or services do not constitute endorsements, and we do not guarantee their quality, safety or effectiveness. You can read our editorial policy.